-- Report highlights efforts to deliver
sustainable value to patients and communities, foster a diverse and
empowered workforce, and operate with exceptional integrity
--
CAMBRIDGE, Mass., July 14,
2022 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today published its first Corporate Responsibility
Report, highlighting its long-standing commitment to deliver
sustainable value to patients with cancer and blood disorders, as
well as the communities in which it operates. The report, which
formalizes the company's efforts to track and report environmental,
social and governance (ESG) standards and initiatives, includes
summaries and performance metrics that demonstrate its
purpose-driven culture and socially conscious business
practices.
"Since we began operations just over a decade ago, Blueprint
Medicines has become a leading precision therapy company, fueled by
our profound sense of mission to drive scientific innovation and
deliver life-changing treatments to patients, as well as make
positive impacts on the multitude of people and communities we
touch along the way," said Kate
Haviland, Chief Executive Officer of Blueprint Medicines.
"As we continue to grow our business, we are committed to being a
force for good, and our first Corporate Responsibility Report is an
important step toward this goal by providing transparency into our
ongoing efforts as well as a foundation for future progress."
The report summarizes the company's activities across five
interconnected domains including patient access and community
engagement, research and development, employees and culture,
environmental sustainability, and governance and integrity, and
adopts accounting standards for the biotechnology and
pharmaceuticals industry from the Sustainability Accounting
Standards Board (SASB). The report was developed by a
cross-functional corporate responsibility working group with
direction from the Executive Team and oversight from the Nominating
and Corporate Governance Committee of Blueprint Medicines' Board of
Directors. It is available for download at
www.BlueprintMedicines.com/Our-Responsibility.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities,
to rapidly and reproducibly translate science into a broad pipeline
of precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Blueprint Medicines' strategy, goals and
anticipated milestones, business plans and focus. The words "aim,"
"may," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this report
are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and important factors
that may cause actual events or results to differ materially from
those expressed or implied by any forward-looking statements
contained in this report, including, without limitation, risks and
uncertainties related to the impact of the COVID-19 pandemic to
Blueprint Medicines' business, operations, strategy, goals and
anticipated milestones, including Blueprint Medicines' ongoing and
planned research and discovery activities, ability to conduct
ongoing and planned clinical trials, clinical supply of current or
future drug candidates, commercial supply of current or future
approved products, and launching, marketing and selling current or
future approved products; Blueprint Medicines' ability and plans in
continuing to establish and expand a commercial infrastructure, and
successfully launching, marketing and selling current or future
approved products; Blueprint Medicines' ability to successfully
expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or
obtain marketing approval for AYVAKIT/AYVAKYT in additional
geographies in the future; the delay of any current or planned
clinical trials or the development of Blueprint Medicines' current
or future drug candidates; Blueprint Medicines' advancement of
multiple early-stage efforts; Blueprint Medicines' ability to
successfully demonstrate the safety and efficacy of its drug
candidates and gain approval of its drug candidates on a timely
basis, if at all; the preclinical and clinical results for
Blueprint Medicines' drug candidates, which may not support further
development of such drug candidates either as monotherapies or in
combination with other agents or may impact the anticipated timing
of data or regulatory submissions; the timing of the initiation of
clinical trials and trial cohorts at clinical trial sites and
patient enrollment rates; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials;
Blueprint Medicines' ability to obtain, maintain and enforce patent
and other intellectual property protection for AYVAKIT/AYVAKYT,
GAVRETO or any drug candidates it is developing; Blueprint
Medicines' ability to develop and commercialize companion
diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current
and future drug candidates; Blueprint Medicines' ability to
successfully expand its operations, research platform and portfolio
of therapeutic candidates, and the timing and costs thereof;
Blueprint Medicines' ability to realize the anticipated benefits of
its executive leadership transition plan; and the success of
Blueprint Medicines' current and future collaborations,
acquisitions, partnerships or licensing arrangements. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in Blueprint Medicines' filings
with the Securities and Exchange Commission (SEC), including
Blueprint Medicines' most recent Annual Report on Form 10-K, as
supplemented by its most recent Quarterly Report on Form 10-Q and
any other filings that Blueprint Medicines has made or may make
with the SEC in the future. Any forward-looking statements
contained in this report represent Blueprint Medicines' views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date. Except as required by law,
Blueprint Medicines explicitly disclaims any obligation to update
any forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-publishes-inaugural-corporate-responsibility-report-301587105.html
SOURCE Blueprint Medicines Corporation